Loading chat...

PA HB1439

Bill

Official Source

Status

Introduced

5/12/2025

Primary Sponsor

Jennifer O'Mara

Click for details

Origin

House of Representatives

2025-2026 Regular Session

AI Summary

  • Amends The Controlled Substance, Drug, Device and Cosmetic Act to automatically reschedule crystalline polymorph psilocybin in Pennsylvania immediately upon FDA approval, aligning state scheduling with federal law

  • Requires the Secretary of Health to transmit notice of any DEA rescheduling of pharmaceutical psilocybin to the Legislative Reference Bureau within five business days for publication in the Pennsylvania Bulletin

  • State rescheduling takes effect 30 days after publication in the Pennsylvania Bulletin

  • Act takes effect immediately upon passage

Legislative Description

Further providing for authority to control.

Last Action

Referred to Health

5/12/2025

Committee Referrals

Health5/12/2025

Full Bill Text

No bill text available